Actinium Pharmaceuticals names Matt David as CFO

Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) appointed Matt David, M.D., as Chief Financial Officer, the company announced Oct. 15, 2026. Dr. David will oversee finance, accounting, capital markets and investor relations, and will serve as the company's principal financial officer.

Dr. David joins Actinium from CorMedix Inc. (Nasdaq: CRMD), where he most recently served as Executive Vice President and Chief Business Officer. He joined CorMedix in 2020 as Executive Vice President and Chief Financial Officer. During his time there, CorMedix received U.S. Food and Drug Administration approval of DefenCath® in 2023, launched the product commercially in 2024, and acquired a commercial anti-infectives company in 2025.

Before CorMedix, Dr. David served as Head of Strategy at Ovid Therapeutics Inc. (Nasdaq: OVID). He also spent more than a decade in healthcare investment banking at BofA Merrill Lynch, Thomas Weisel Partners and Piper Jaffray, and worked as an equity research associate at Lehman Brothers covering the pharmaceutical sector.

Dr. David holds an M.D. from NYU School of Medicine, completed a surgery residency at Beth Israel Hospital, and received an undergraduate degree in Chemistry from Dartmouth College.

Actinium Chairman and CEO Sandesh Seth said in a statement that Dr. David "has been a public company CFO, an interim CEO and a CBO, and he has helped guide a company from late-stage development through FDA approval, commercial launch and a transformational acquisition."

Actinium is a clinical-stage company developing targeted radiotherapies, with a pipeline that includes ATNM-400, Actimab-A and Iomab-ACT, among other programs.

You May Also Be Interested In

• Proofpoint to acquire Varonis in $6.3 billion all-cash deal
• RBC Capital Reiterates Outperform Rating on GFL Environmental (GFL:CN) (GFL)
• Digital Brands Group names Todd Kucinski VP of sports partnerships